Journal article · 2024 · Open access
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
JAMA, 332(7), 551 · Published 31 May 2024 · DOI 10.1001/jama.2024.9217
In brief
“Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial” is a 2024 journal article by Lin Zhao and 8 co-authors, published in JAMA. OpenAlex counts 169 citations as of 22 November 2026, which puts it in the top 1% of works published in 2024 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 169
- Most cited in
- 2026 (82)
- Field-weighted impact
- 30.27
- References
- 27
- Authors
- 9
Abstract
Importance: Obesity has become a global public health concern and China has the largest number of affected people worldwide. Objective: To assess the efficacy and safety of treatment with tirzepatide for weight reduction in Chinese adults with obesity or overweight and weight-related comorbidities. Design, Setting, and Participants: This randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 29 centers in China from September 2021 to December 2022 included Chinese adults (aged ≥18 years) with a body mass index (BMI) greater than or equal to 28 or greater than or equal to 24 and at least 1 weight-related comorbidity, excluding diabetes. Interventions: Participants were randomly assigned (1:1:1) to receive once-weekly, subcutaneous 10-mg (n = 70) or 15-mg (n = 71) tirzepatide or placebo (n = 69), plus a lifestyle intervention, for 52 weeks. Main Outcomes and Measures: Co-primary end points were the percent change in body weight from baseline and weight reduction of at least 5% at week 52. Efficacy and safety analyses were performed on an intention-to-treat population. Results: Of 210 randomized participants (103 [49.0%] female; mean [SD] age, 36.1 [9.1] years; body weight, 91.8 [16.0] kg; BMI, 32.3 [3.8]), 201 (95.7%) completed the trial. The mean change in body weight at week 52 was -13.6% (95% CI, -15.8% to -11.4%) with tirzepatide 10 mg, -17.5% (95% CI, -19.7% to -15.3%) with tirzepatide 15 mg, and -2.3% with placebo (difference between 10 mg and placebo, -11.3% [95% CI, -14.3% to -8.3%; P < .001]; difference between 15 mg and placebo, -15.1% [95% CI, -18.2% to -12.1%; P < .001]). The percentage of participants achieving body weight reductions of 5% or greater was 87.7% with tirzepatide 10 mg, 85.8% with tirzepatide 15 mg, and 29.3% with placebo (P < .001 for comparisons with placebo). The most frequent treatment-emergent adverse events with tirzepatide were gastrointestinal. Most were mild to moderate in severity, with few events leading to treatment discontinuation (<5%). Conclusions and Relevance: In Chinese adults with obesity or overweight, once-weekly treatment with tirzepatide 10 mg or 15 mg resulted in statistically significant and clinically meaningful weight reduction with an acceptable safety profile. Trial Registration: ClinicalTrials.gov Identifier: NCT05024032.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zhao, L., Cheng, Z., Lu, Y., Liu, M. R., Chen, H., Zhang, M., Wang, R., Yuan, Y., & Li, X. (2024). Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA, 332(7), 551. https://doi.org/10.1001/jama.2024.9217
MLA 9
Zhao, Lin, et al. “Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.” JAMA, vol. 332, no. 7, 2024, p. 551. https://doi.org/10.1001/jama.2024.9217.
Chicago
Zhao, Lin, Zhifeng Cheng, Yibing Lu, Ming Rong Liu, Hong Chen, Min Zhang, Rui Wang, Yuan Yuan, and Xiaoying Li. 2024. “Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.” JAMA 332 (7): 551. https://doi.org/10.1001/jama.2024.9217.
Harvard
Zhao, L. et al. (2024) ‘Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial’, JAMA, 332(7), p. 551. doi:10.1001/jama.2024.9217.
IEEE
L. Zhao et al., “Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial,” JAMA, vol. 332, no. 7, p. 551, 2024, doi: 10.1001/jama.2024.9217.
BibTeX
@article{zhao2024tirzepatide,
title = {{Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial}},
author = {Zhao, Lin and Cheng, Zhifeng and Lu, Yibing and Liu, Ming Rong and Chen, Hong and Zhang, Min and Wang, Rui and Yuan, Yuan and Li, Xiaoying},
journal = {JAMA},
year = {2024},
volume = {332},
number = {7},
pages = {551},
doi = {10.1001/jama.2024.9217},
url = {https://doi.org/10.1001/jama.2024.9217}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 17 | |
| 2025 | 70 | |
| 2026 | 82 |
Its field-weighted citation impact is 30.27: it has been cited 30.27 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- tirzepatide
- obesity
- weight loss
- weight-related comorbidities
- Chinese adults
- overweight
- lifestyle intervention
- GLP-1 receptor agonists
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Zhao, L., Cheng, Z., Lu, Y., Liu, M. R., Chen, H., Zhang, M., Wang, R., Yuan, Y., & Li, X. (2024). Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA, 332(7), 551. https://doi.org/10.1001/jama.2024.9217
How many times has this paper been cited?
169 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Lin Zhao, Zhifeng Cheng, Yibing Lu, Ming Rong Liu, Hong Chen, Min Zhang, Rui Wang, Yuan Yuan, Xiaoying Li.
What is the DOI of this paper?
10.1001/jama.2024.9217, permanently at https://doi.org/10.1001/jama.2024.9217. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.